Food and Drug Administration (FDA)
NEWS
A former CEO of Vyera and other activist investors are pushing a slate of new company directors who would steer control of Phoenixus and Vyera away from Shkreli.
While the drug showed significant improvement in patients on a 200mg daily dose of filgotinib, it may not be promoted in the states any time soon.
Acting commissioner of the U.S. FDA asked the independent Office of the Inspector General to investigate how the FDA and representatives of Biogen interacted prior to the FDA’s approval of the company’s Aduhelm (aducanumab) for Alzheimer’s disease.
The two companies said a booster dose given six months after the second dose had a consistent tolerability profile while still creating high immune responses against the Alpha and Beta variant.
The study, which compared the same treatment combination to pomalidomide plus dexamethasone covered 495 patients from over a hundred hospitals in 21 countries.
Ivermectin has become a contentious issue as to whether it effectively prevents and treats COVID-19. Several studies suggest it is effective, while others have indicated it is not.
bluebird bio is hitting back at Spark Therapeutics over the use of the word “spark” involving the company’s “Be the Spark” campaign against sickle cell disease.
The expanded approval was made based on positive data from a second interim analysis of the Phase II KEYNOTE-629 trial.
Continuing studies and news about COVID-19 around the world keeps coming in. Here’s a look.
JOBS
IN THE PRESS